ArticleNPJ precision oncology2025

Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial.

Eliana Pivetta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.